Th e phosphatidylinositol three kinase pathway may be the most often mutated pathway in breast cancer, with mutation and/or

amplifi cation of your genes encoding the PI3K catalytic subunits p110 and p110B, the PI3K regulatory subunit p85, receptor tyrosine kinases such as human epidermal growth factor receptor two and fi broblast progress element receptor one, the PI3K activator K Ras, the PI3K eff ectors AKT1, AKT2, and phosphoinositide dependent kinase 1, and reduction with the lipid phosphatases PTEN and INPP4B.